Home » Stocks » ABUS

Arbutus Biopharma Corporation (ABUS)

Stock Price: $2.69 USD -0.07 (-2.54%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $2.70 +0.01 (0.37%) Jul 30, 7:58 PM
Market Cap 270.71M
Revenue (ttm) 7.54M
Net Income (ttm) -78.62M
Shares Out 93.43M
EPS (ttm) -0.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $2.69
Previous Close $2.76
Change ($) -0.07
Change (%) -2.54%
Day's Open 2.74
Day's Range 2.68 - 2.86
Day's Volume 2,209,075
52-Week Range 2.31 - 5.87

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Why investors are watching these 7 penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Informat...

Other stocks mentioned: ARPO, CRBP, DBGI, JFU, NBY, NXE
3 weeks ago - PennyStocks

Phase 2a trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNα-2a in subjects with chronic hepatit...

3 weeks ago - GlobeNewsWire

The expected start of combination clinical trials has H.C. Wainwright bullish on shares of Arbutus Biopharma Corp. (NASDAQ:ABUS).

3 weeks ago - Benzinga

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-of-care...

Other stocks mentioned: VACC
3 weeks ago - Benzinga

WARMINSTER, Pa. and OXFORD, United Kingdom, July 06, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) and Vaccitech plc (Nasdaq: VACC) today announced that the companies have entere...

3 weeks ago - GlobeNewsWire

MENDHAM, N.J. and WARMINSTER, Pa., June 29, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the companies have entered into a cli...

1 month ago - GlobeNewsWire

Are these hot penny stocks on your morning watchlist? The post Best Penny Stocks to Buy Right Now?

Other stocks mentioned: MRIN, SB, UAMY, AHT, SENS, TNXP
1 month ago - PennyStocks

Arbutus Biopharma Corporation (NASDAQ: ABUS) announced the presentation of five abstracts at the European Association for the Study of the Liver International Liver Congress for AB-729 in chronic hepati...

1 month ago - Benzinga

AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks

1 month ago - GlobeNewsWire

Conference Call and Webcast to discuss the new data being presented at EASL  scheduled for 8:00 AM ET, Monday, June 28, 2021

1 month ago - GlobeNewsWire

Arbutus (ABUS) delivered earnings and revenue surprises of 4.55% and -45.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV...

2 months ago - GlobeNewsWire

WARMINSTER, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chroni...

3 months ago - GlobeNewsWire

Arbutus Biopharma Corp (NASDAQ: ABUS), X-Chem Inc, and Proteros biostructures GmbH have entered into discovery, research, and license agreement focused on discovering novel inhibitors targeting the SARS...

3 months ago - Benzinga

Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks

3 months ago - GlobeNewsWire

WARMINSTER, Pa., March 16, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chroni...

4 months ago - GlobeNewsWire

Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 6.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 50.00% year over year to ($0.23), which missed ...

4 months ago - Benzinga

AB-729, Arbutus' proprietary subcutaneously delivered RNAi agent, demonstrates robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favor...

4 months ago - GlobeNewsWire

Arbutus Biopharma (ABUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

Assembly Biosciences Inc (NASDAQ: ASMB) and Arbutus Biopharma Corp (NASDAQ: ABUS) initiated a Phase 2 trial evaluating the former's vebicorvir (VBR), combined with the latter's AB-729 and standard-of-ca...

5 months ago - Benzinga

Trial will evaluate Assembly's core inhibitor candidate, vebicorvir, with Arbutus' RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy

5 months ago - GlobeNewsWire

Arbutus Biopharma Corporation is an industry-leading early clinical-stage biopharmaceutical company focused on developing a cure for patients with chronic hepatitis B virus.

6 months ago - Seeking Alpha

2021 objectives leverage positive momentum in Arbutus' Hepatitis B research and development programs

6 months ago - GlobeNewsWire

WARMINSTER, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic...

6 months ago - GlobeNewsWire

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks ( –1.44 log10, N=7, p

7 months ago - GlobeNewsWire

Data released today expands on November 15, 2020 AASLD presentation

8 months ago - GlobeNewsWire

Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau , suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted

8 months ago - GlobeNewsWire

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

WARMINSTER, Penn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chron...

8 months ago - GlobeNewsWire

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Arbutus (ABUS) delivered earnings and revenue surprises of -35.00% and -15.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

WARMINSTER, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chro...

10 months ago - GlobeNewsWire

Mean HBsAg reduction of 1.23 log10 IU/mL at week 12 with a favorable safety  and tolerability profile 

10 months ago - GlobeNewsWire

WARMINSTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chro...

10 months ago - GlobeNewsWire

America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic.

Other stocks mentioned: AZN, JNJ, MRNA, NVAX, PFE
10 months ago - 24/7 Wall Street

SOUTH SAN FRANCISCO, Calif. and WARMINSTER, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that the ...

11 months ago - GlobeNewsWire

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

Is (ABUS) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

Short-term investors appear impatient.

11 months ago - The Motley Fool

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Arbutus (ABUS) delivered earnings and revenue surprises of -8.70% and -17.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 1% in pre-market trading after the company reported Q2 results.

11 months ago - Benzinga

Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020

11 months ago - GlobeNewsWire

The biotech sector in the stock market has been on fire lately.

11 months ago - Seeking Alpha

WARMINSTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chron...

11 months ago - GlobeNewsWire

Here's what drove shares of these healthcare stocks through the roof last month.

Other stocks mentioned: ALT, OMI
11 months ago - The Motley Fool

About ABUS

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-83... [Read more...]

Industry
Biotechnology
CEO
William Collier
Employees
76
Stock Exchange
NASDAQ
Ticker Symbol
ABUS
Full Company Profile

Financial Performance

In 2020, ABUS's revenue was $6.91 million, an increase of 15.02% compared to the previous year's $6.01 million. Losses were -$63.75 million, -58.53% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for ABUS stock is "Buy." The 12-month stock price forecast is 5.92, which is an increase of 120.07% from the latest price.

Price Target
$5.92
(120.07% upside)
Analyst Consensus: Buy